What has to be true for a durvalumab biosimilar to enter clinical development?
A durvalumab biosimilar program typically starts with a stepwise comparability strategy and then moves into clinical testing that checks whether the biosimilar is highly similar to the reference product in ways that matter for safety and efficacy.
That usually means companies pursue:
- Analytical and functional similarity (structure, binding, Fc-related properties, and other “quality attributes”).
- Clinical pharmacology studies to confirm comparable exposure and behavior in humans (often focusing on pharmacokinetics and pharmacodynamics).
- Immunogenicity assessment, since monoclonal antibody biosimilars can differ in how patients develop anti-drug antibodies even when they are highly similar.
- Phase 3 (or at least a pivotal confirmatory trial) designed to show no clinically meaningful differences in efficacy and safety, using endpoints supported by the reference product’s mechanism and approved indications.
What does the clinical development program usually look like (phases and endpoints)?
A typical durvalumab biosimilar clinical development sequence includes:
Phase 1 (healthy volunteers or a patient-relevant setting)
- Confirm pharmacokinetics (PK) and pharmacodynamics (PD) comparability.
- Evaluate safety and tolerability.
- Measure immunogenicity (anti-drug antibodies and neutralizing antibodies where applicable).
Phase 3 (confirmatory comparative efficacy and safety)
- Compare the biosimilar versus the reference durvalumab on an efficacy endpoint expected to be sensitive to differences, but also aligned with the reference clinical evidence.
- Continue head-to-head safety monitoring and immunogenicity tracking over longer follow-up.
The exact endpoints and inclusion criteria depend on the intended indication, regulatory approach, and what data regulators require for that biosimilar in that region.
Which indication is commonly used for the “pivotal” biosimilar trial?
For durvalumab biosimilars, companies often select an indication that:
- Matches the reference product’s established clinical use (most notably in non-small cell lung cancer where durvalumab is widely used after chemoradiation),
- Provides a clinically meaningful efficacy endpoint that can be compared head-to-head, and
- Is supported by robust clinical follow-up so safety and immunogenicity differences would be detectable.
The choice of indication can also be influenced by trial feasibility and the regulator’s expectations for extrapolation of results to other approved indications.
How do companies handle immunogenicity in biosimilar trials?
Immunogenicity is usually built into both early-phase and confirmatory studies, with predefined rules for:
- Timing of anti-drug antibody assessments,
- How results are interpreted (including whether neutralizing antibodies are present),
- How any differences could affect safety or treatment discontinuation.
Durvalumab biosimilar programs also track infusion reactions and hypersensitivity-related events because antibody therapies can trigger immune-mediated responses even when efficacy is comparable.
How do regulators typically judge “biosimilarity” for durvalumab?
Regulators generally expect evidence that the biosimilar is highly similar to the reference product, meaning any remaining differences (if present) do not translate into clinically meaningful differences.
Practically, that means the program aims to support:
- Comparable PK/PD and exposure,
- Comparable efficacy outcomes in a sensitive population,
- Comparable safety profile,
- Comparable immunogenicity profile.
If all these align, regulators may allow extrapolation to other indications of the reference product, depending on how similar mechanisms of action and target biology are across those indications.
What timelines are typical for a durvalumab biosimilar program?
Timelines vary by region, trial size, and enrollment pace, but a biosimilar program usually takes multiple years because it needs:
- Manufacturing lots and analytical bridging,
- A controlled clinical PK/PD and immunogenicity assessment,
- A confirmatory comparative trial with enough follow-up for efficacy and safety signals.
Companies also need time for regulatory submission packages that tie together manufacturing comparability, clinical pharmacology, and confirmatory efficacy/safety data.
What are the main risks or failure points?
Common risks in monoclonal antibody biosimilar development include:
- Non-matching PK exposure (showing clinically relevant differences in clearance or distribution),
- Immunogenicity discrepancies (higher rate or different kinetics of anti-drug antibodies),
- Safety signals that diverge from the reference product beyond predefined tolerances,
- Trial design choices that use an endpoint or population that is not sensitive enough to detect differences regulators care about.
Are there different program strategies depending on region (EU vs US vs other)?
Yes. While the core comparability logic is similar, expectations differ:
- EU pathways often rely heavily on a “stepwise” comparability package culminating in clinical confirmation.
- US and other frameworks can also be comparability-driven but may emphasize different aspects of what is needed for interchangeability or specific regulatory determinations.
Those regional expectations can change trial endpoints, population selection, and how extrapolation arguments are built.
What happens after clinical data: what comes next for approval and switching?
After clinical development, the company submits a biosimilar application with:
- Full analytical comparability,
- Clinical PK/PD, immunogenicity, and efficacy/safety evidence,
- The proposed labeling and any extrapolated indications.
For some regions, “switching” or “interchangeability” may require additional evidence beyond standard biosimilarity.
---
Sources
No sources were provided in the prompt, so I can’t cite any specific clinical development program details (e.g., specific trial names, phases, comparators, endpoints, or sponsoring companies) without additional information or links.